The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
We reported the successful administration of infliximab for late‐onset OKT3‐resistant rejection in two patients, who presented persistent ulcerative inflammation of the ileal graft after intestinal transplantation (ITX). Based on this experience, the present study demonstrated our long‐term experience with infliximab for different types of rejection‐related and inflammatory allograft alterations. Infliximab administration (5 mg/kg body weight (BW)) was initiated at a mean of 18.2 ± 14.1 months after transplantation. The number of administrations per patient averaged 8.4 ± 6.7. Repeat dosing was timed according to clinical signs and graft histology in addition to serum‐levels of tumor necrosis factor alpha (TNFα), lipopolysaccharide binding protein (LBP) and C‐reactive protein (CRP). Infliximab was successful in the following patients: patients with late‐onset OKT3‐ and steroid‐refractory rejection who presented persistent ulcerative alterations of the ileal graft (n = 5), patients with ulcerative ileitis/anastomositis, who did not show typical histological rejection signs (n = 2), and one patient with early‐onset OKT3‐resistant rejection. Infliximab was not successful in one patient with early‐onset OKT3‐resistant rejection that was accompanied by treatment‐refractory humoral rejection. In conclusion, infliximab can expand therapeutic options for late‐onset OKT3‐ and steroid‐refractory rejection and chronic inflammatory graft alterations in intestinal allograft recipients....
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.